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Control of erythropoiesis by IgA?
Coulon et al., Nat Med 2011; 17: 1456–1465; doi:10.1038/nm.2462
The regulation of erythropoiesis, that is, the commitment 
of hematopoietic stem cells to erythroid progenitors and 
precursors, is a complex process. It needs stem cell factor 
and erythropoietin (Epo) for the proliferation and survival 
of erythroid cells. In the absence of Epo, late erythroblasts 
undergo apoptosis. Moreover, erythroid precursors require 
iron for hemoglobin production. Cellular iron uptake occurs 
through binding of iron-laden transferrin to transferrin recep-
tor 1 (TfR1), whose expression on the cell surface is essen-
tial for erythropoiesis. In addition to its major role in iron 
metabolism, TfR1 is a multiligand receptor that par ticipates in 
a wide array of cellular functions. Now, Coulon et al. demon-
strate that TfR1 is a receptor for A1-isotype immunoglobulins 
(IgA1). IgA1 is mainly synthesized in bone marrow. Although 
in humans 90% of circulating IgA1 is monomeric, the remain-
ing 10% is polymeric. It is the polymeric IgA1 that, after bind-
ing to TfR1, is able to promote erythroblast proliferation under 
conditions of poor cellular growth in vitro, as for instance in 
the presence of suboptimal Epo concentrations. Moreover, 
hypoxic stress in mice leads to increased amounts of polymeric 
IgA1 and erythroblast expansion in vivo. This is in favor of a 
new paracrine loop in the control of erythropoiesis in situ, 
in addition to the well-known endocrine loop involving Epo 
secretion by the kidney (Figure). Cellular signaling pathways 
subsequent to the activation of TfR1 by either polymeric IgA1 
or iron-transferrin include mitogen-activated protein kinase 
and phosphatidylinositol 3-kinase. The study thus shows that 
the interaction between polymeric IgA1 and TfR1 stimu-
lates erythropoiesis in both physiological and pathological 
situations. This observation could be of interest for patients 
with chronic kidney disease, who often have functional iron 
deficiency and frequently receive high, potentially harmful 
doses of intravenous iron.
Targeting of the polymeric IgA1–TfR1 pathway might become 
an alternative to high-dose iron administration in the treatment 
of ineffective erythropoiesis owing to insufficient iron availabil-
ity in the anemia of chronic diseases.
Tilman B. Drüeke
Equilibrative nucleoside  
transporter 1 regulates 
postischemic blood flow during 
acute kidney injury in mice
Grenz et al., J Clin Invest 2012; 122: 693–710; doi:10.1172/JCI60214
Adenosine is a nucleoside, locally released in response to cellular 
stress, such as ischemia–reperfusion injury (IRI) and inflam-
mation, which allows tissues to adapt to hypoxia. Extracellular 
adenosine largely accumulates from the breakdown of adenine 
nucleotides by a family of nucleotidases, including CD39 and 
CD73. Adenosine exerts its effects through binding to any of 
four G protein−coupled receptors, designated as A1. Passive 
downhill extracellular to intracellular transport of adenosine via 
equilibrative nucleoside transporters (ENTs) leads to metabolism 
by adenosine deaminase and adenosine kinase and termination 
of adenosine signaling. A series of elegant and comprehensive 
experiments by Grenz et al. demonstrated that one ENT isoform 
(ENT1) controls extracellular adenosine levels during kidney 
IRI, which reduces the extent of injury via adenosine action on 
endothelial Adora2b receptors. Maneuvers that block adeno-
sine uptake (Ent1–/– mice, dipyridamole (an inhibitor of ENTs)) 
reduce kidney IRI, an effect reversed with polyethylene glycol-
modified adenosine deaminase, an enzyme that does not cross 
cell membranes and metabolizes extracellular adenosine. ENT1 is 
expressed on basolateral membranes and is downregulated during 
hypoxia, making it likely to protect kidneys from IRI. Reconstitu-
tion of human ENT1 in Ent1–/– mice through a lentiviral trans-
duction system reversed the protective phenotype to IRI in these 
mice. To determine the target of adenosine action, the authors 
examined the effect of dipyridamole on IRI in Adora1, -2a, 
-2b, and -3 knockout mice. They found protection in all groups 
except Adora2–/– mice, suggesting that the effect was mediated by 
Adora2b. Targeted deletion of Adora2b in proximal tubules and 
endothelial cells demonstrated that endothelial Adora2b mediated 
the tissue-protective effect of adenosine.
These results demonstrate the important homeostatic role 
of ENT1 and endothelial-cell Adora2b in mediating tissue 
protection by adenosine during kidney IRI and support the 
development of selective agonists for Adora2b receptors for the 
treatment of acute kidney injury (AKI). These studies contribute 
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Polymeric A1-isotype immunoglobulins (pIgA1) as a modulator of 
Epo sensitivity. Variation in red blood cell number depends on Epo 
concentration. Epo-hyposensitive erythroblasts undergo apoptosis, 
whereas Epo-hypersensitive erythroblasts survive. Hypoxia increases 
renal Epo production and Epo-hyposensitive erythroblasts. It also 
induces plasma cell production of pIgA1, which in turn increases the 
sensitivity of erythroblasts to Epo. Epo, erythropoietin.
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to the well-established literature supporting the role of Adora1 
and Adora2a receptors in kidney IRI. Further studies will be 
needed for translation into human AKI.
Mark Okusa
Mitochondrial fission triggered  
by hyperglycemia is mediated  
by ROCK1 activation in podocytes 
and endothelial cells
Wang et al., Cell Metab 2012; 15: 186–200; doi:10.1016/j.cmet.2012.01.009
While previous studies have shown a crucial role of oxidative 
stress induced by hyperglycemia in diabetic complications, 
including nephropathy, a precise mechanism of generation of 
oxidative stress remains unknown. Wang et al. generated type 
1 and type 2 diabetic mouse models with targeted deletions of 
ROCK1 and found amelioration of albuminuria and histological 
changes. They also established an inducible podocyte-specific 
knock-in mouse expressing a constitutively active mutant of 
ROCK1 (cA-ROCK1) and observed promotion of albuminuria, 
podocyte effacement, and mesangial matrix expansion. Mito-
chondria are a major source of oxidative stress. The authors 
performed electron paramagnetic resonance of isolated mito-
chondria from glomeruli and observed increased oxidative 
stress in diabetic mitochondria. Electron microscopic examina-
tions of diabetic kidneys showed increased mitochondrial frag-
mentation in podocytes. The mitochondrial fragmentation was 
prevented in knockout of ROCK1 (Figure). These observations 
led the authors to investigate dynamin-related protein-1 (Drp1), 
a key component of the mitochondrial fission machinery. They 
observed a marked increase in Drp1 in mitochondria-enriched 
fractions of the kidney glomeruli of diabetic mice. The increase 
in mitochondrial Drp1 levels was abolished in ROCK1-deficient 
diabetic mice. Conversely, mitochondrial Drp1 was significantly 
increased in the kidney glomeruli of podocyte-specific cA-
ROCK1 mice. A functional role of ROCK1 in hyperglycemia-
induced mitochondrial reactive oxygen species was confirmed in 
cultured podocytes and endothelial cells. Immuno precipitation 
of cell lysates cultured under high-glucose conditions revealed 
binding of ROCK1 with Drp1. On the basis of the consensus 
sequence motif of ROCK substrates, the authors identified 
Ser600 in the mouse Drp1 as a potential phosphorylation site 
for ROCK1. Analysis using phosphospecific Drp1 antibodies 
showed that high glucose stimulation increased phosphorylation 
of Drp1 at Ser600 in a ROCK1-dependent manner.
In conclusion, Wang et al. reported that ROCK1 mediates 
hyperglycemia-induced mitochondrial fission by phosphoryla-
tion and subsequent recruitment of Drp1 to the mitochondria. 
These findings provide important insights into the unexpected 
role of ROCK1 in a signaling cascade that regulates mitochon-
drial dynamics and generation of oxidative stress in diabetic 
nephropathy. 
Masaomi Nangaku
EXTending functional  
BENEFIT to ECD donor kidneys
Medina Pestana et al., Am J Transplant 2012; 12: 630–639; doi:10.1111/
j.1600-6143.2011.03914.x
Extended-criteria donors (ECDs) are an increasingly common 
source of donor kidneys worldwide. The long-term outcome of 
these kidneys with conventional calcineurin inhibitor-based 
immunosuppressive therapy has been shown to be worse than 
that seen with standard-criteria donors. Belatacept is the first 
FDA-approved costimulation blocker, which allows the avoid-
ance of calcineurin inhibitors and provides effective immunosup-
pression for renal transplantation. Medina Pestana et al. report 
the 3-year outcomes of the BENEFIT-EXT trial, a prospective 
randomized controlled study of belatacept in comparison with 
cyclosporine in ECD kidney transplantation. In this study, 543 
patients assigned an ECD kidney transplant were randomized to 
receive belatacept of middle intensity (MI) or low intensity (LI) 
or control cyclosporine. After 3 years of follow-up, there were 
109 subjects in the MI, 114 in the LI, and 100 in the cyclosporine 
group. The major findings were comparable 3-year patient sur-
vival in the three groups. Despite an increased risk of early rejec-
tion, there were comparable acute rejection rates between the 
groups over the entire 3-year period. However, patients treated 
with the calcineurin inhibitor had greater progression to chronic 
kidney disease stage 4/5 (44%) compared with the belatacept-
treated group (30%). The mean calculated glomerular filtration 
rate (GFR) was 11 ml/min higher in belatacept-treated patients. 
The major adverse events in the belatacept-treated patients 
included post-transplantation lymphoproliferative disease (eight 
cases) and tuberculosis (six cases).
This study provides evidence of improved GFR over time in 
costimulation blocker-treated patients, with a reduction in the 
development of GFRs less than 30 ml/min. Using novel agents 
such as belatacept provides the potential to tailor immunosup-
pressive therapy to improve graft survival and function. This 
new class of agents is a welcome addition to the transplant 
physician’s armamentarium.
P. Toby Coates
 Three-dimensional reconstruction of mitochondria in podocytes 
from serial sections of electron microscopic images. The mitochondria 
in wild-type diabetic mice were fragmented into short spheres. In contrast, 
podocytes from diabetic ROCK1-deficient mice preserved a typical tubular 
network of mitochondria.
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